For personal use only

Similar documents
For personal use only

For personal use only

Investment in MGC Pharmaceuticals

World leader in navigated, non-invasive brain stimulation therapy and diagnosis

LifeHealthcare Investor Day 5 October 2016

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Investor presentation. Bioshares Biotech Summit July 2017

For personal use only

USPSTF Draft Recommendations Investor Call. October 6, 2015

Investor Presentation

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX

FORM8-K HILLENBRAND,INC.

XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease

Tamsulosin Hydrochloride 0.4 mg Capsule

For personal use only

Brisa Concessão Rodoviária. 1Q 2017 Traffic Update

Itamar Medical. December Investors Presentation.

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

34 th Annual J.P. Morgan Healthcare Conference

PROACTIVE INVESTOR PRESENTATION

Transforming IVF and Biological Separations Presentation by Executive Chairman, Alison Coutts

INVESTOR PRESENTATION

Mental Toronto Hydro

January 30, 2018 Dow Wilson President and Chief Executive Officer

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Genomic Health. Kim Popovits, Chairman, CEO and President

NOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

AGM Presentation For the year to 30 September February 2016

Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018

Important Notices. BASIS CPD Points PN/50971/1516/g

Developing Xanamem for Alzheimer s Dementia

WOLFSON FERTILITY CENTRE. Wolfson Fertility Centre

PATENCY-1 Top-Line Results

Advancing Pancreatic & Liver Cancer Treatment

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET FORECAST

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

Presentation to 2019 JP Morgan Healthcare Conference

DS-8201 Strategic Collaboration

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes

Investor Presentation December 2014 ASX: MEB

THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH ANONYMOUS DONOR SPERM

Riesling Base Metal Project pxrf Soil Geochemistry

Cavosonstat Phase 2 Trial Results. November 28 th, 2016

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

DISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Annual Shareholders Meeting

STRATEGIC PLAN Australian Kookaburra Kids Foundation Incorporated ABN

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss

Global In-Vitro-Fertilization Market: Trends and Opportunities ( )

RULES OF CONDUCT OF INSIDERS RESPECTING

GOVERNING BOARD. Assisted Conception (IVF): Review of access criteria. Date of Meeting 21 January 2015 Agenda Item No 13. Title

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

MEDICAL DEVICE PATH TO MARKET UPDATE

Investor Presentation January 2015 ASX: MEB

For personal use only

PLEO-CMT Top-line Results. Presentation October 16, 2018

Sirtex Medical Ltd Buy

FIRSTQUARTER2018 RESULTSPRESENTATION

THE NEXT GROWTH PHASE

Forward-Looking Statements

CONSENT FOR CRYOPRESERVATION OF EMBRYOS

N a s d a q : I N S Y

For personal use only ANNUAL GENERAL MEETING PRESENTATION ZELDA THERAPEUTICS NOVEMBER ASX:ZLD

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

Recommended Interim Policy Statement 150: Assisted Conception Services

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

Not an Offer for Securities

CHOOSING WISELY FOR KINGSTON PROPOSED CHANGES TO LOCAL HEALTHCARE - IVF

DMX-200 for Diabetic Kidney Disease

GI Dynamics, Inc. Q2 16 Quarterly Shareholder Brief 8/11/16

Investor Presentation

Designing a Smoke-Free Future

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

Improving the lives of people with neurological conditions. Annual General Meeting Neurotech International Limited (ASX: NTI) November 2017

Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD

Enel Américas 1Q 2018 results

Novo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights

www. isotopeworld.com Advanced Medical Isotope Corporation

Avenue Therapeutics, Inc. August 2016

INVESTOR PRESENTATION

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

New Ideas. Better Medicines. Third Quarter Financial Results Conference Call

Annual Results 2017 & Business Update 13 April 2018

West Hampshire Clinical Commissioning Group Board

Shareholder Presentation Annual Meeting 2018

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

SUBJECT: Cannabis legislation and implications for the City of Burlington

HILLENBRAND INDUSTRIES INC

DR.NEIL FRAZER CHIEF EXECUTIVE OFFICER & MANAGING 1

THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH IDENTIFIED DONOR SPERM

Transcription:

Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016

DISCLAIMER 2 The material in this presentation has been prepared by Virtus Health Limited ABN 80 129 643 492 ( Virtus Health ) and is general background information about Virtus Health s activities current at the date of this presentation. The information is given in summary form and includes financial and other information and does not purport to be complete. Information in this presentation, including forecast financial information should not be considered as advice or a recommendation to investors or potential investors and does not take into account investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice when deciding if an investment is appropriate. Persons needing advice should consult their stockbroker, solicitor, accountant or other independent financial advisor. The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Certain statements made in this presentation are forward-looking statements. These forwardlooking statements are not historical facts but rather are based on Virtus Health Limited s current expectations, estimates and projections about the industry in which Virtus Health operates, and beliefs and assumptions. Words such as anticipates, expects, intends,, plans, believes, seeks, estimates, and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Virtus Health, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Virtus Health cautions investors and potential investors not to place undue reliance on these forward-looking statements, which reflect the view of Virtus Health only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Virtus Health will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. In addition, a number of figures have been calculated on the basis of assumed exchange rates, as set out in this presentation. To the maximum extent permitted by law, neither Virtus Health nor its related bodies corporate, directors, officers, employees, agents, contractors, advisers nor any other person, accepts, and each expressly disclaims, any liability, including without limitation any liability arising from fault or negligence, for any errors or misstatements in, or omissions from, this presentation or any direct, indirect or consequential loss arising from the use of this presentation or its contents or otherwise arising in connection with it.

One child in every Australian classroom 3

CONTENTS 4 VIRTUS HEALTH Overview 5 Financial Track Record 7 Leading Minds, Leading Science 8 Factors Driving Growth 11 Advanced Technology 14 Strategic Plan 16

VIRTUS HEALTH - WORLD LEADER IN FERTILITY CARE 5 Market leader and largest provider of fertility services in Australia and Ireland with a growing presence in Singapore One of the largest fertility practices globally First publically listed fertility business Continued growth via international acquisition and greenfield development 18,719 cycles globally up 9.6% (FY 15 17,064) Total treatments up 14% to 34,269 (FY15: 30,025) Reputation for clinical and scientific excellence 116 fertility specialists and over 1200 professional staff Investment in clinical and scientific research and new technologies delivers improved patient outcomes and growth Early adopter of new technologies driving growth Distinctive, diversified and vertically integrated model with multiple sources of revenue Fertility, Day Hospitals and Specialised Diagnostics * Total treatments include fresh cycles, frozen embryo transfers and IUIs

VIRTUS HEALTH NETWORK OF CARE Graph title 6 For personal use only

SOLID FINANCIAL TRACK RECORD 7 Reported Revenue Graph title Reported EBITDA NPAT Pre-minorities FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 Note: Charts are on a reported basis. NPAT pre minorities.

LEADING MINDS, LEADING SCIENCE 8 Focus on clinical and scientific-led innovation and patient outcomes drives long term growth Industry leader in fertility and scientific practice for over 30 years Recognised brands regarded for quality and service Track record of attracting and retaining high quality doctors, specialist staff Ongoing investment in advanced sciences and specialised diagnostics delivers improved patient outcomes and revenue growth Experienced clinical and management team with ability to drive practice growth and add value

DOCTORS OF VIRTUS HEALTH 9 One of the most successful medical collaborations internationally

WHO COMES TO ASK FOR OUR HELP? 10 40% of the patients that see fertility specialists have non IVF treatment

FACTORS DRIVING GROWTH 11 Demographic & Social Trends Infertility is a medical condition affecting 1 in 6 couples of reproductive age globally Growing female population, rising maternal age and global fertility rates in decline Rising incidence of conditions impacting fertility e.g. obesity and chlamydia Greater community awareness and acceptance of IVF Increasing number of same sex & single women starting families using our donor services Young adults increasingly living with parents we meet soulmates in our late 20s/early 30s and seek relationship and financial security before starting a family Evolution of Clinical Practice & Service Delivery Virtus cycles 18,719 FY12 FY13 FY14 FY15 FY16 Australian Cycles International Cycles MOST SIGNIFICANT : Advancements in Technology and international diversification

DIVERSIFIED REVENUE MIX 12 For personal use only

FIRST MOVER IN TECHNOLOGY ADOPTION 13 Specialised diagnostics & scientific advancements improving success rates & delivering ARS to new patient segments New operating division Virtus Diagnostics established in FY15 Offering spans entire spectrum of reproductive health (prepregnancy to pre-natal screening) Virtus a first mover in adopting new gene based technologies Virtus delivers Australia s first babies using karyomapping in 2015 Introduction of fertility panel and preconception gene screening

ADVANCED TECHNOLOGY 14 Studying the chromosomal structure of the eggs sperm Selecting the healthiest sperm Using timelapse imaging to study embryo growth

GENETIC SCREENING OF EMBRYOS 15 For personal use only

REGULATORY ENVIRONMENT 16 Proactive participation in regulatory review to facilitate balanced debate reflective of our patients needs. Australia Government review of Medicare Benefits Schedule expected National Health and Medical Research Council ( NHMRC ) reviewing regulations for sex selection for family balancing Ireland Government considering funding for fertility services currently privately funded Proposed change to egg donation anonymity Singapore Alignment with Australia s RTAC Conservative environment growing interest in PGD/S access in Singapore

VIRTUS HEALTH STRATEGIC PLAN 17 Vision: To help women and men achieve their aspirations to create a family

THANK YOU